BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs4950928
,
PTEN
,
Angiogenesis
,
Influenza
,
Prostate
,
Biofuel
,
Acetaminophen
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
tubulin binding
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Vestibular nuclei superior
Midbrain
Parietal lobe
Medulla oblongata
Frontal lobe
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Tubulin binds to the cytoplasmic loop of TRESK background K⁺ channel in vitro.
A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubul…
Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin…
A structure-based design of new C2- and C13-substituted taxanes: tubulin binding affinities and exte…
Tubulin-binding cofactor B is a direct interaction partner of the dynactin subunit p150(Glued).
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic…
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer
Study of Tesetaxel in Japanese Patients With Solid Tumors
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Study of TPI 287 in Patients With Advanced Malignancies
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ